Friday, March 22, 2019

Living Beyond Beast Cancer Conference Philadelphia 2018

On September 28, 2018, I attended the Living Beyond Breast Cancer Conference that was co-hosted by The Triple Negative Breast Cancer Foundation in Philadelphia. A lot of  promising research is still ongoing for Triple Negative Breast Cancer... PARP Inhibitors was FDA approved in October 2018 for BRCA positive metastatic TNBC.  Immunotherapy and Antibody-drug conjugates is also emerging in TNBC clinical trials with favorable results in complete response in metastatic Triple Negative Breast Cancer. 


My beautiful hotel room view of
Philadelphia skyline

No One Fights Alone!
TNBC sisters Sara K. and Melissa

Hayley Dinerman, Co-founder and President of
Triple Negative Breast Cancer Foundation
https://tnbcfoundation.org

Diagnosed with Triple Negative Breast Cancer
before the age of 60?

Promising Immunotherapy research
for TNBC still in clinical trials

The safety of Pembrolizumab Monotherapy
has demonstrated as being  favorable as
a first-line therapy with PD-L1 positive
Metastatic Triple Negative Breast Cancer.

Breast Cancer Oncologist, Reshma L. Mahtani
Identifying the different subtypes
of Triple Negative Breast Cancer

PARP Inhibitors as an emerging target for
Metastatic TNBC patients that are also
BRCA positive of the gene mutation

Most breast cancer in African women are
triple negative

Who's at higher risk of Triple Negative
Breast Cancer?

Brain metastases is much higher in advanced
Triple Negative Breast Cancer than
other breast cancer subtypes

Me and the ladies of the TNBC Foundation
Allison Axenrod,  Amy Mustica, Melissa Paskvan,
Arlene Brothers and Hayley Dinerman

Fighting for a TNBC
targeted therapy breakthrough!

Pow!

"Rocky"

Breast cancer sisters 
Terlisa Sheppard and Melissa

#KissThis4MBC

Melissa and Josh Levin of
 lymphedivas.com

TNBC sister, Sara K. showing off
her new sleeve just purchased from
a vendor, 
lymphedivas.com


Cheers! 
Party-crasher of a cancer fundraiser!

Triple Negative Breast Cancer sisters
Addys S. and Melissa